Erasca Inc. (NASDAQ:ERAS) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 27, Erasca announced positive preliminary Phase 1 data for ERAS-0015, a pan-RAS molecular glue targeting solid tumors. In patients with non-small cell lung cancer, the therapy achieved a 62% response rate in late-line settings, rising to 75% for those previously treated with platinum therapies. Results for pancreatic cancer were also significant, showing a 50% response rate at the highest recom ...